Anti-arrhythmic device therapy has limits in improving the prognosis of patients with cardiac amyloidosis  by Kojima, Toshiya et al.
Journal of Arrhythmia 28 (2012) 242–246Contents lists available at SciVerse ScienceDirectJournal of Arrhythmia1880-42
http://d
n Corr
E-mjournal homepage: www.elsevier.com/locate/joaOriginal ArticleAnti-arrhythmic device therapy has limits in improving the prognosis
of patients with cardiac amyloidosisToshiya Kojima, MD, PhDa, Yasushi Imai, MD, PhDa,n, Katsuhito Fujiu, MD, PhDa,b,
Takeki Suzuki, MD, PhDa, Hiroaki Sugiyama, MDa, Kazuo Asada, MDa,
Kohsuke Ajiki, MDe, Noriyuki Hayami, MD, PhDf, Yuji Murakawa, MD, PhDf,
Ryozo Nagai, MD, PhDa,b,c,d
a Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo, Tokyo 113-8655, Japan
b Translational Systems Biology and Medicine Initiative, The University of Tokyo Graduate School of Medicine, Japan
c Global COE, The University of Tokyo Graduate School of Medicine, Japan
d Translational Research Center, The University of Tokyo Graduate School of Medicine, Japan
e Cardiovascular Center, JR Tokyo General Hospital, Japan
f Fourth Department of Internal Medicine, Teikyo University School of Medicine, Japana r t i c l e i n f o
Article history:
Received 25 November 2011
Received in revised form
5 January 2012
Accepted 10 January 2012
Available online 24 April 2012
Keywords:
Implantable cardioverter-deﬁbrillator
Pacemaker
AL amyloidosis76/$ - see front matter & 2012 Japanese Hea
x.doi.org/10.1016/j.joa.2012.01.002
esponding author. Tel.: þ81 3 3815 5411; fax
ail address: imaiycard-tky@umin.org (Y. Imaia b s t r a c t
Immunoglobulin light chain (AL) amyloidosis has poor long-term prognosis. Sudden cardiac death (SCD) is
a common cause of death in patients with cardiac AL amyloidosis. Prophylactic anti-arrhythmic device
therapy has been suggested as an option to reduce this risk. We address this issue by reviewing 4 cases of
cardiac AL amyloidosis with anti-arrhythmic device therapy. One patient who had an atrioventricular block
underwent pacemaker implantation, and the other 3 patients received implantable cardioverter-deﬁbril-
lator (ICD) implantation for ventricular arrhythmia. All of the 3 ICD implantation cases received appropriate
shock therapy for ventricular arrhythmia in the early stage. However, they soon died due to pulseless
electrical activity (PEA) or severe heart failure. The median survival period for our 4 cases was as short as
12.3 months. In particular, the 3 patients who required ICD had worse prognoses. Thus, ICD implantation
therapy for chemotherapy-resistant cardiac AL amyloidosis may prevent SCD but may not prolong the
patient’s survival. There are no arguments against pacemaker implantation for cardiac amyloidosis with
conduction disturbance; however, the clinical beneﬁt of ICD indication for ventricular tachyarrhythmia is
limited. Further extensive clinical research should be performed to deﬁnitively determine the effects of ICD
implantation on cardiac AL amyloidosis.
& 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Amyloidosis refers to conditions in which amyloid proteins are
abnormally deposited in organs. Symptoms vary widely and
depend on the kinds of overproduced amyloid proteins and the
sites of amyloid deposition. The 2 major types of amyloidosis are
immunoglobulin light chain (AL) amyloidosis and amyloid A
protein (AA) amyloidosis. AL amyloidosis is a systemic disease
that is characterized by extracellular tissue deposition of immu-
noglobulin heavy or light chain fragments. This extracellular
accumulation leads to characteristic histologic changes and organ
dysfunction. Amyloid deposits can occur in a variety of organs,
including the heart, kidney, liver, gastrointestinal tract, and
autonomic nervous system. Cardiac involvement occurs in up to
30–50% of patients with AL amyloidosis and less than 5% with AA
amyloidosis [1,2]. AL amyloidosis has a poor long-term prognosisrt Rhythm Society. Published by E
: þ81 3 3818 6673.
).[3,4], the median survival may be as short as 4–6 months, and the
major causes of death are arrhythmia and heart failure, although
several chemotherapeutic regimens have been attempted in some
selected patients with AL amyloidosis. It has been reported that
heart failure accounted for 51% of the deaths [5]. In the early
stage, patients often present diastolic dysfunction followed by
systolic dysfunction, which is refractory to standard therapies for
heart failure at late disease stages [6]. In addition, many patients
suffer from several kinds of arrhythmia.
Arrhythmic features of amyloid cardiomyopathy are conduc-
tion abnormalities such as sick node dysfunction, second- and
third-degree atrioventricular block, atrial ﬁbrillation, and ventri-
cular arrhythmia. The conduction system is often affected in
patients with amyloid cardiomyopathy. Although the sinus node
may be most involved, electrophysiologic dysfunction appears to
be most common in the His-Purkinje system [7]. A permanent
pacemaker is indispensable and commonly used for bradycardiac
arrhythmia, but several previous reports suggest a limited effect
in reducing the risk of sudden death [1,8].lsevier B.V. All rights reserved.
Fig. 1. Case 2: sustained ventricular tachycardia. After appropriate shocks, his QRS
complex widened. The ICD could not capture ventricular myocardium, and the
ventricular tachycardia or ﬁbrillation could not be detected because of the low-
amplitude of the intracardiac electrocardiogram.
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conduction or anatomical obstacles that are labile to ventricular
tachyarrhythmia. Arrhythmias are independently predictive of
sudden cardiac death (SCD) [9]. SCD is common in patients with
cardiac AL amyloidosis, and prophylactic implantable cardiover-
ter-deﬁbrillators (ICDs) have been suggested as an option to
reduce this risk [10,11]. However, pulseless electrical activity
(PEA) appears to be 1 signiﬁcant cause of SCD in these patients,
probably because the mechanical properties of an amyloid heart
are markedly injured due to abundant harmful protein deposition,
intracardiac ischemia, and deletion of cardiac myocytes [12].
ICD implantation is the most reliable therapy for preventing
SCD in patients who are ischemic, dilated, or hypertrophic, or
have other diseases that places them at high risk for SCD.
However, the role of ICD therapy in preventing SCD due to cardiac
amyloidosis is still unclear. For the present study, we reviewed
4 cases of AL amyloidosis in our department from 2004 to 2008
that underwent anti-arrhythmic device therapy.
1.1. Case 1
A 54-year-old man had chest discomfort and underwent an
endoscopic examination. A raised lesion was detected in his sto-
mach, and histological analysis of the resected specimen demon-
strated amyloid deposition in the gastric and duodenal mucosa. He
was diagnosed with AL amyloidosis based on biological and patho-
logical examinations. Chest X-rays revealed a normal cardiac silhou-
ette, and a low voltage of the limb leads was present in his
electrocardiogram. The serum B-type natriuretic peptide (BNP) level
was 57.4 pg/ml, and the left ventricular systolic function was
preserved at this time. Though he was treated with 2 courses of
chemotherapy containing melphalan and dexamethasone (16 mg
and 40 mg, respectively, for 4 days), the treatment had little effect
on the progression of the disease. Three months after the initial
diagnosis, paroxysmal atrial ﬂutter and ﬁbrillation were documen-
ted. The number of atrial tachyarrhythmia episodes increased, and
frequent electrical cardioversion was needed. In parallel, ventricular
ectopies and non-sustained ventricular tachycardia were documen-
ted. Catheter ablation to the cavotricuspid isthmus for atrial ﬂutter
and ICD implantation to prevent SCD due to ventricular tachyar-
rhythmia (Medtronic, VIRTUOSO DR/D164AWG) were performed.
However, 1 week after the ICD implantation, an electrical storm
with repetitive appropriate shocks from the device was observed.
The electrical storm disappeared after effectively supplementing
with anti-arrhythmic drugs. However, 7 months after the initial
diagnosis, the patient died of PEA and severe heart failure following
sporadic ventricular tachycardia. The serum BNP level was elevated
to 2601.4 pg/ml just before death.
1.2. Case 2
A 63-year-old man had palpitations and shortness of breath on
exertion. Chest X-rays revealed an enlarged cardiac silhouette,
and a low voltage of the limb leads, a pseudoinfarct pattern in V1-
2 leads, and inverted T waves in the V4-6 leads were present.
Although the left ventricular ejection fraction was preserved
(55%), concentric left ventricular hypertrophy, granular sparkling,
and severe diastolic dysfunction were observed on a cardiac
echocardiogram. At this time, his serum BNP level was 1070 pg/ml.
He collapsed at his home following cardiopulmonary arrest and was
urgently resuscitated by bystanders. After resuscitation, a complete
atrioventricular block was detected at a nearby hospital, and a
temporary transvenous pacemaker electrode was inserted. He was
diagnosed with AL amyloidosis based on the pathological ﬁndings of
a myocardial biopsy. While the cause of the cardiopulmonary arrest
is still unknown, ventricular tachyarrhythmia was strongly suspectedbased on the circumstances of his condition. ICD implantation was
performed (St. Jude Medical, ATLASþDR V-243). Three days after ICD
implantation, sustained ventricular tachycardia was documented and
successfully terminated with appropriate shock therapy. However, 9
days after ICD implantation, shocks for sustained monomorphic
ventricular tachycardia were delivered 4 times. Several medications,
including amiodarone, nifekalant, and magnesium, were adminis-
tered to prevent ventricular tachyarrhythmia. At this stage, the serum
BNP level was elevated to 3380.9 pg/ml. Thirteen days after ICD
implantation, polymorphic ventricular tachycardia had developed.
After appropriate shocks, post-shock pacing could not capture the
ventricular myocardium due to a worsening of the pacing threshold.
At the end, tachycardia sensing failed to function properly due to the
low-amplitude of the intracardiac ventricular tachycardia or ﬁbrilla-
tion waves (Fig. 1). The patient died of uncontrollable ventricular
arrhythmia 4 months after the initial diagnosis.
1.3. Case 3
A 49-year-old man experienced shortness of breath and
palpitations upon exertion. Chest X-rays revealed an enlarged
cardiac silhouette, and the BNP level was 208.9 pg/ml at this time.
The electrocardiogram (ECG) showed a left axis deviation, low
voltage in the limb leads, QS patterns in the V1-2 leads, and an
inverted T in the V3-6 leads. A detailed examination revealed left
ventricular hypertrophy and decreased left ventricular systolic
function. He was diagnosed with AL amyloidosis based on a
stomach biopsy. An electrophysiological study revealed normal
sinus and atrioventricular nodal function. Ventricular tachycardia
and ventricular ﬁbrillation were not induced. The patient under-
went high-dose melphalan chemotherapy and autologous per-
ipheral blood hematopoietic cell transplantation (PBSCT) for the
treatment of AL amyloidosis. After 2 months of chemotherapy
supported by PBSCT, sinus arrest with a ventricular escape beat
was detected; thus, temporary cardiac pacing was immediately
started. Two days after temporary ventricular pacing, the patient
Fig. 3. Case 4: ventricular tachyarrhythmia that resulted in PEA. Sensing and
pacing failure due to severe heart failure as well as low-amplitudes in the
intracardiac electrocardiograms were present.
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cessfully terminated by repetitive electrical deﬁbrillation. An ICD
was inserted (Medtronic, MAXIMO DR7278), and the patient had
an uneventful life for 6 months. However, the patient died
suddenly 6 months after the ICD implantation (10 months after
the AL amyloidosis diagnosis). Unfortunately, the patient was
transferred to another hospital, and we could not access the exact
cause of his sudden death because we could not examine the logs
stored in his ICD devices in detail. However, at least no ventricular
tachyarrhythmia was documented from the time of the ICD
implantation until his death.
1.4. Case 4
A 63-year-old man had lower extremity edema. His urinalysis
showed Bence Jones proteinuria, which is evidence of a monoclonalFig. 2. Case 4: typical ﬁndings of cardiac amyloidosis. His ECG showed a
trifascicular block and a low voltage of the limb leads, and his chest X-rays
revealed an enlarged cardiac silhouette. An impaired left ventricular systolic
function, thickened cardiac walls with a ‘‘granular sparkling,’’ and severe diastolic
dysfunction was presented in his echocardiograms.plasma cell proliferative disorder. An AL amyloidosis diagnosis was
established via a skin biopsy. Chest X-rays revealed an enlarged
cardiac silhouette. His electrocardiogram showed a trifascicular
block and a low voltage of the limb leads. The BNP level was
57.4 pg/ml at this time. Echocardiograms showed left ventricular
hypertrophy but a preserved left ventricular systolic function. The
calculated ejection fraction was 67%, and the serum BNP level was
57.5 pg/ml. He was started on MP therapy (18 mg melpha-
lanþ60 mgm PSL for 4 days). Subsequently, the anticancer drug
L-PAM was administered, and autologous peripheral blood stem cell
transplantation was performed to treat the AL amyloidosis. A high
dose of dexamethasone was also administered. However, the patient
was resistant to these chemotherapies. During the course of the
disease, echocardiograms showed impaired left ventricular systolic
function, thickened cardiac walls with a ‘‘granular sparkling,’’ and
severe diastolic dysfunction. These are presented in Fig. 2 as typical
ﬁndings of cardiac amyloidosis. He experienced shortness of breath
during exercise 14 months after the initial diagnosis. Around the
same time, he experienced several episodes of faintness and
syncope. In his electrocardiogram, his atrioventricular conduction
abnormality progressed to a complete AV block. An electrophysio-
logical study documented the conduction block at the infra-His
level, and no ventricular arrhythmias were induced. Therefore, we
implanted a cardiac pacemaker rather than an ICD. However, his
cardiac function gradually deteriorated. Remarkably, the amplitude
of the R wave voltages in his pacemaker decreased gradually at his
pacemaker clinic from 15mV to 4–5mV. His heart failure was
refractory to standard therapeutic regimens, and he was hospita-
lized repeatedly. Twenty-eight months after his diagnosis, he
suddenly developed cardiopulmonary arrest due to pacing failure,
followed by PEA with ventricular arrhythmia as well as PEA while in
the hospital (Fig. 3). At this time, we did not administer any anti-
arrhythmic agents, and the laboratory testing the day before his
death did not show signiﬁcant acidosis or hyper/hypokalemia.
Despite urgent and advanced cardiac life support efforts, he could
not be resuscitated.2. Discussion
The standard treatment of patients with primary AL amyloidosis
who are not candidates for hematopoietic cell transplantation
generally consists of chemotherapy, including a combination of
melphalan and prednisone [5,13]. Especially in AL amyloidosis,
chemotherapy may have curative or partial effects on this disease
concerning stabilization or improvement of symptoms. In contrast,
some patients cannot survive sufﬁciently long to receive adequate
Table 1
List of cases with AL amyloidosis with cardiac involvement.
Case Age Sex Chemotherapy
(efﬁcacy)
EF (%) BNP (pg/ml)
(at the diagnosis)
Arrhythmia Device Prognosis
(months)
1 54 M Not effective 78 57.4 AFL, VT ICD 7
2 63 M Not performed 55 1070 SSS, VF ICD 4
3 49 M Not effective 40 208.9 SSS, VF ICD 10
4 63 M Not effective 67 57 AV block PM 28
EF: ejection fraction, BNP: B-type natriuretic peptide measured at the time of diagnosis of amyloidosis, AFL: atrial ﬂutter, VT: ventricular tachycardia, SSS: sick sinus
syndrome, VF: ventricular ﬁbrillation, AV block: atrioventricular nodal block, Prognosis: survival period from diagnosis of cardiac amyloidosis to death.
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often associated with a risk of treatment-related mortality [5,13].
Cardiac involvement is the predominant manifestation of this
disease, and patients with AL amyloidosis suffer progressive
cardiomyopathy and SCD. Exertional syncope, which is a sign of
severe restrictive cardiomyopathy and is associated with a high
mortality several months after the initial event, often results in
SCD [6]. The incidence of SCD in AL amyloidosis is only 10–30%
[14,15]. In addition, the causes of SCD are reported not only to be
ventricular tachyarrhythmia but also PEA [12].
There is a high prevalence of bradyarrhythmia in cardiac
amyloidosis, and there are no alternatives to pacemaker implan-
tation for those patients. In contrast, regardless of the low
incidence of ventricular arrhythmia, ICD implantation was
selected for preventing SCD as previously reported [16,17]. There-
fore, it is difﬁcult to decide when to perform an ICD implantation.
Some anecdotal reports of ICD therapy in patients with cardiac
amyloidosis are available [10,11]. However, Kristen et al. reported
19 cases with cardiac amyloidosis, and these patients died as a
result of PEA and other diagnoses not amenable to ICD therapy
[16]. In particular, Kristen et al. reported that there was signiﬁ-
cant difference in the progression of the left ventricular wall
thickness and the low-voltage pattern in the electrocardiogram
between non-survivors and survivors. They concluded that better
methods for selecting patients with arrhythmia-associated SCD
are required to elucidate the efﬁcacy of ICD therapy in AL
amyloidosis. All of our 4 cases had a low-voltage pattern in the
electrocardiogram. Three of the 4 cases had a left ventricular wall
thickness (the exception was case 1). All of the 3 patients who
underwent chemotherapy were not responsive to the therapy.
Two of the 3 patients with an ICD received shocks for ventricular
tachyarrhythmias early on; however, these patients soon died due
to PEA or severe heart failure. In Case 2, the patient had no
episode of ventricular tachyarrhythmias after his ICD implanta-
tion. Soon after the implantation, ventricular tachyarrhythmias
were documented. ICD implantation and related shock delivery
may be labile to ventricular tachyarrhythmias and may deterio-
rate the clinical course and the disease progression. Recently, ICD
shocks have been shown to impair cardiac function, leading to
heart failure and worsening prognosis by inducing an electrical
storm of ventricular tachyarrhythmias. This is 1 potential reason
that ICD implantation therapy may lead to early-stage SCD
instead of prolonging the patient’s survival. The second patient
with an implanted ICD had SCD; however, unfortunately, the
exact cause of his sudden death could not be determined by
examining the logs stored in his ICD device. In Case 4, a wide QRS
tachycardia was not detected in the pacemaker. As noted above, it
was remarkable that the amplitude of the R wave voltages in the
pacemaker decreased gradually. A low amplitude of intracardiac
potential may be an indicator of myocardial impairment.
All 4 patients with symptomatic cardiac AL amyloidosis had
poor prognoses. The median survival period for these 4 patients
was 12.3 months (minimum¼4 months, maximum¼28 months)(Table 1). The patient in Case 2, whose BNP level was the highest
of the 4 patients, had the shortest survival period. However,
careful consideration is required to determine whether there is a
correlation between the BNP level at the time of diagnosis of
cardiac amyloidosis and the survival period. Considering the
standard guidelines for ICD implantation in preventing arrhyth-
mia-associated CSD, patients with poor prognoses should perhaps
be excluded from for ICD implantation [18].
Given our experience with anti-arrhythmic device therapy in AL
amyloidosis with cardiac involvement, the application of ICD
therapy may have limitations in these patients. In particular, in
patients that did not respond to chemotherapy, ICD therapy could
not prevent CSD due to PEA within 12 months. It was difﬁcult to
determine the difference between non-survivors and survivors in
our cases. We should consider what differences exist or do not exist
between successful cases of ICD implantation. The differences may
depend on the situation or stage of the disease, including the
severity of the heart failure, as shown by the BNP level, or the
accumulation of amyloid proteins. Additional cases and statistically
analyses will be required to determine which patients with cardiac
amyloidosis can beneﬁt from ICD implantation.Conﬂict of interest
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